The global recombinant protein market size reached US$ 170.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 279.7 Billion by 2028, exhibiting agrowth rate (CAGR) of 11.4% during 2023-2028.
A recombinant protein refers to a modified or altered protein that is encoded by recombinant DNA. The recombinant DNA molecule consists of a plasmid in which the genes for a target protein are cloned. It is produced either by molecular cloning or polymerase chain reaction (PCR). Some of the common product variants include kinase proteins, human insulin, structural proteins, adhesion molecules and receptors, immune response proteins, etc. Recombinant protein is primarily utilized in the development of novel therapies for chronic and rare diseases. It finds widespread adoption in numerous biopharmaceutical companies, academic and research institutes, contract research organizations, etc.
Recombinant Protein Market Trends:
The elevating prevalence of several chronic diseases along with the increasing demand for novel treatment options is primarily driving the global recombinant protein market. In addition to this, the rising investments in the field of protein engineering and the improving focus on protein-based drug development are further augmenting the market growth. Moreover, numerous government bodies are funding R&D activities for the introduction of advanced techniques in proteomics and genomics, which are significantly impacting the global market for recombinant protein. Besides this, the advent of recombinant protein expression technology has led to the development of high-quality autoantigens that are widely used in immunotherapy procedures. Additionally, the growing requirement for recombinant proteins for accurate measurement of biomarkers in the field of drug discovery is also creating a positive outlook for the global market. Apart from this, the rising penetration of latest molecular biology approaches for biopharming to reduce proteolysis of recombinant proteins or prevent the partial or total loss of glycosylation is expected to bolster the global recombinant protein market over the forecast period.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global recombinant proteinmarket report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, application and end user.
Breakup by Product:
Breakup by Application:
Drug Discovery and Development
Breakup by End User:
Pharmaceutical and Biopharmaceutical Companies
Academic and Research Institutes
Contract Research Organization
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abcam plc, Amgen Inc., Bio-RAD Laboratories Inc., Bio-Techne Corporation, Bps Bioscience Inc., Enzo Biochem Inc., Genscript Biotech Corporation, Merck KGaA, Novo Nordisk A/S, ProSpec-Tany TechnoGene Ltd, Sanofi S.A. and Thermo Fisher Scientific.
Base Year of the Analysis
Product, Application, End User, Region
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global recombinant protein market was valued at US$ 170.9 Billion in 2022.
We expect the global recombinant protein market to exhibit a CAGR of 11.4% during 2023-2028.
The rising prevalence of several chronic diseases, along with the increasing demand for recombinant protein variants, such as kinase proteins, human insulin, adhesion molecules and receptors, etc., across biopharmaceutical companies and contract research organizations, is primarily driving the global recombinant protein market.
The sudden outbreak of the COVID-19 pandemic has led to the growing adoption of recombinant protein for developing novel therapies to combat the spread of the coronavirus infection.
Based on the application, the global recombinant protein market has been segregated into drug discovery and development, academic research, biotechnology research, biopharmaceutical production, and others. Among these, drug discovery and development currently exhibits clear dominance in the market.
Based on the end user, the global recombinant protein market can be bifurcated into pharmaceutical and biopharmaceutical companies, biotechnology companies, academic and research institutes, contract research organization, and others. Currently, pharmaceutical and biopharmaceutical companies hold the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global recombinant protein market include Abcam plc, Amgen Inc., Bio-RAD Laboratories Inc., Bio-Techne Corporation, Bps Bioscience Inc., Enzo Biochem Inc., Genscript Biotech Corporation, Merck KGaA, Novo Nordisk A/S, ProSpec-Tany TechnoGene Ltd, Sanofi S.A., and Thermo Fisher Scientific.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.